Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn's disease
(CD), is a costly condition in terms of morbidity and healthcare utilization, with an increasing …

Background Currently, 2 coprimary end points are used by health authorities to determine
the effectiveness of therapeutic interventions in patients with Crohn's disease (CD) …

Background: Inflammatory bowel disease (IBD) is a chronically relapsing disease with a
continuous need for proactive monitoring to decide appropriate treatments and follow-up …

Despite advances in our understanding of the pathophysiology underlying inflammatory
bowel disease, there remains a significant need for biomarkers that can differentiate …

There is increasing interest in the concept of 'treat‐to‐target'in inflammatory bowel disease
as a mechanism to standardize management and prevent complications. While clinical …

Inflammatory bowel diseases [IBD] such as Crohn's disease [CD] and ulcerative colitis [UC]
are complex conditions presenting with a wide range of phenotypes. Given major variation …

Crohn's disease and ulcerative colitis represent the two main forms of the idiopathic chronic
inflammatory bowel diseases (IBD). Currently available blood and stool based biomarkers …

GVA The gold standard for diagnosing and following patients with inflammatory bowel
disease (IBD) has been endoscopy, which is quite invasive. While a flexible sigmoidoscopy …

The number of patients with inflammatory bowel disease (IBD) is increasing worldwide.
Endoscopy is the gold standard to assess the condition of IBD. The problem with this …

There is currently no gold standard test for the diagnosis of inflammatory bowel disease
(IBD). Physicians must rely on a number of diagnostic tools including clinical and …